Using Lactobacillus Plantarum to Prevent Clostridium Difficile Infections in Hospitalized Patients
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department
NA · Medical University of Silesia · NCT06859437
This study is testing if a specific probiotic can help prevent Clostridium difficile infections in hospitalized patients who are taking antibiotics and immunosuppressive treatments.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Silesia (other) |
| Locations | 1 site (Poland, Silesian Voivodeship) |
| Trial ID | NCT06859437 on ClinicalTrials.gov |
What this trial studies
This study aims to determine if the Lactobacillus plantarum 299v strain can reduce the risk of Clostridium difficile infections (CDI) in patients receiving antibiotics and immunosuppressive treatment in a nephrology and transplantation ward. A total of 300 adult patients will be enrolled and randomly assigned to receive either the probiotic or a placebo for three months. The study will be conducted over a period of 36 months at the Medical University of Silesia in Poland. The primary focus is on patients who are particularly vulnerable to CDI due to their treatment regimens.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are undergoing immunosuppressive treatment and antibiotic therapy.
Not a fit: Patients who do not consent to participate in the study will not benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could significantly lower the incidence of CDI in at-risk hospitalized patients, improving their overall health outcomes.
How similar studies have performed: While the use of probiotics for preventing CDI has been explored in other studies, this specific approach using the LP299v strain in this patient population is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * over 18 years old * organ transplantation or receiving immunosuppressive drugs for any other reasons * antibiotics therapy Exclusion Criteria: * no consent to participate in the study
Where this trial is running
Poland, Silesian Voivodeship
- Department of Nephrology, Transplantation and Intenal Medicine Medical University of Silesia — Poland, Silesian Voivodeship, Poland (RECRUITING)
Study contacts
- Study coordinator: Sylwia Dudzicz-Gojowy, PhD, MD
- Email: sdudzicz@sum.edu.pl
- Phone: +48322591432
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Clostridioides Difficile Infection